UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~April 159, 2012 (~~March~~April 134, 2012)

_______________

BIOCANCELL THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware	000-53708	20-4630076
(State or other jurisdiction of incorporation)	Commission File Number	(IRS Employer Identification No.)

Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem, Israel, 97775

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 972-2-548-6555

(Former name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events.

OnFollowing ~~March~~its ~~13,~~announcement ~~2012,~~regarding ~~BioCancell~~the ~~Therapeutics~~successful ~~Inc.~~achievement ~~("BioCancell")~~of ~~received~~the ~~results~~primary endpoint (drug safety) of ~~its~~a Phase I/IIa clinical trial of BC-819 as a treatment for ~~patients with~~ advanced ovarian cancer ~~who~~following ~~have~~the ~~previously~~failure ~~failed~~of ata ~~least one~~ standard treatment., ~~The~~and ~~results~~its ~~show~~intention ~~that~~to ~~BioCancell~~expand ~~met~~ the clinical trial's ~~primary~~in ~~endpoint~~order ~~(treatment~~to obtain more data on drug safety). Inand ~~addition~~efficacy, aton April 4, 2012, BioCancell Therapeutics Inc. announced that it had received the ~~highest~~required ~~dose~~regulatory ~~given~~approvals ~~(240~~to ~~mg),~~expand ~~signs~~the ofclinical ~~efficacy~~trial ~~were~~and ~~observed~~will commence patient recruitment.

~~The~~As ~~trial~~previously ~~took~~reported, ~~place~~the insafety aprofile ~~number~~ of ~~medical~~the ~~centers~~drug inwas ~~Israel,~~found ~~with~~to 11be ~~late-stage~~satisfactory, ~~heavily~~even ~~pretreated~~at ~~patients~~the ~~participating~~highest dosage (~~following~~240 anmg) ~~average~~which ofwas ~~four~~administered ~~complete~~three ~~cycles of chemotherapy each)~~times. ~~The~~In ~~patients~~light ~~each received one~~ of ~~three doses of BC-819 - 60 mg~~this, ~~120~~BioCancell mgintends ~~and~~to ~~240~~treat ~~mg (the~~an ~~highest~~additional ~~dosage~~six ~~group).~~patients Asin ~~required by~~ the ~~FDA,~~expanded ~~the~~ trial, ~~protocol~~each ~~was~~receiving ~~designed~~12 tocontinuous ~~focus~~weekly ontreatments ~~testing~~of ~~the~~240 ~~safety~~mg of BC-819,. asThe ~~this~~purpose ~~was~~of the ~~first~~expanded ~~time that dosages of this magnitude had been used in a clinical~~ trial, ~~and~~is ~~that~~to anexamine ~~intraperitoneal~~the ~~mode~~safety of ~~administration was used. Therefore,~~ the ~~protocol~~treatment ~~included~~with ~~a 4~~BC-~~week~~819 ~~break~~at ina ~~the~~high ~~treatment~~dosage inover ~~order to evaluate any possible adverse events~~time.

~~The~~In ~~primary~~addition, ~~endpoint~~BioCancell ofintends ~~the~~to ~~trial~~examine ~~was~~over ~~evaluating~~a longer period the ~~safety~~phenomenon ofobserved, ~~the~~whereby ~~treatment~~patients ~~(establishing~~receiving the ~~maximum~~highest ~~tolerated~~dosage ~~dose~~showed ~~and~~a ~~the~~decrease, ~~presence~~and oreventually absence, of ~~any~~ascites ~~dose-limiting~~(a ~~toxicity).~~fluid Ascontaining nocancerous ~~dose-limiting~~cells ~~toxicity~~that ~~was~~gathers ~~recorded,~~in the ~~optimal~~abdominal ~~dosage~~cavity). ~~was~~This ~~determined~~effect tocontinued beas ~~the~~long ~~maximum~~as ~~dosage given in~~ the ~~trial~~patients -received ~~240 mg~~treatment. InAscitic ~~addition,~~fluid ~~the~~is ~~results~~a ~~show~~significant ~~that~~side noeffect ~~serious~~for ~~adverse~~ovarian ~~events~~cancer ~~were linked to the drug~~patients, ~~meaning~~which ~~that~~adversely ~~BioCancell~~affects ~~has~~their ~~fully~~quality ~~met~~of ~~the~~life ~~trial's~~and ~~primary~~indicates ~~endpoint~~patient deterioration.

~~During~~The ~~the~~expanded ~~course of the~~ trial, ~~ascitic~~will ~~fluid~~take ~~levels~~place ~~dropped~~in ~~and~~five ~~the~~Israeli ~~ascites~~medical ~~disappeared~~centers: ~~for~~Hadassah, ~~all~~Carmel, ~~patients~~Meir, inWolfson ~~the~~and ~~high~~Sheba ~~dosage~~Medical ~~group as long as they received treatment~~Centers. ~~Ascites~~The ~~are~~regulatory acommittees ~~fluid~~approving ~~containing~~clinical ~~cancerous~~trials ~~cells that builds up~~ in ~~the~~each ~~peritoneal~~medical ~~cavity.~~center ~~They~~have ~~are~~approved athe ~~significant~~expanded ~~side effect for ovarian cancer patients that severely affect quality of life~~trial, and results are anexpected ~~indicator~~within ofone ~~deterioration of the patient's condition~~year.

In light of these trial results, BioCancell will act to expand the trial by treating an additional group of patients at the highest dosage (240 mg), in a treatment regime designed to provide more information regarding treatment efficacy and safety, with details to be provided one regulatory approvals are received.

This filing contains "forward-looking" statements, including statements that may relate to the further development and potential safety and efficacy of BC-819 or other products under development by BioCancell, as well as BioCancell's development strategy. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of BioCancell to differ materially from those indicated by these forward-looking statements, including, among others, the risk that the U.S. Food and Drug Administration may require changes to the protocols and informed consents for clinical trials, which changes may have a material adverse effect on the timing of, and BioCancell's ability to conduct, those clinical trials, risks related to the clinical advancement of BioCancell's products, including, but not limited, to the risk that clinical trials may not demonstrate safety and efficacy sufficient to obtain the requisite regulatory approvals or to result in a marketable product and risks related to the potential for others to develop similar products. BioCancell does not undertake any obligation to update forward-looking statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOCANCELL THERAPEUTICS, INC.
Dated: March 15, 2012	By:	/s/ Avraham Hampel
Dated: April 9, 2012	By:	/s/ Avraham Hampel
		Avraham Hampel
		Company Secretary

Filing Compare · BIOCANCELL THERAPEUTICS INC.